CSIMarket
 
Puretech Health Plc  (PRTC)
Other Ticker:  
 
 
Price: $25.8500 $0.27 1.056%
Day's High: $25.95 Week Perf: 5.51 %
Day's Low: $ 25.85 30 Day Perf: 8.75 %
Volume (M): 1 52 Wk High: $ 33.07
Volume (M$): $ 13 52 Wk Avg: $24.40
Open: $25.95 52 Wk Low: $17.08



 Market Capitalization (Millions $) 7,231
 Shares Outstanding (Millions) 280
 Employees -
 Revenues (TTM) (Millions $) 16
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) 466
 Capital Exp. (TTM) (Millions $) 2

Puretech Health Plc
PureTech Health Plc, founded in 2002, is a biotechnology company that focuses on developing and commercializing innovative treatments for various healthcare challenges. The company aims to address significant medical needs by utilizing strategic partnerships and collaborations with leading academic institutions, scientific entrepreneurs, and industry experts.

PureTech Health has a unique approach to healthcare innovation, employing a cross-disciplinary team of experts in various fields, including biology, medicine, engineering, and data science. This interdisciplinary approach allows the company to explore diverse technologies and treatment modalities, including microbiome-based therapies, targeted drug delivery systems, and digital health solutions.

The company operates through an internal pipeline of wholly-owned subsidiaries, such as Karuna Therapeutics, Gelesis, Vedanta Biosciences, and Akili Interactive, among others. Each subsidiary focuses on a specific therapeutic area or technological platform, allowing for efficient development and commercialization of their respective products.

PureTech Health Plc's innovation-driven business model aims to identify and validate emerging science and technology, shepherd them through clinical development, and ultimately launch them as successful, commercially viable products. With a strong emphasis on collaboration and intellectual property, the company strives to position itself at the forefront of healthcare innovation.


   Company Address: 6 Tide Street Boston 2210 MA
   Company Phone Number: 482-2333   Stock Exchange / Ticker: NASDAQ PRTC
   PRTC is expected to report next financial results on April 27, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Neurogene Inc

Neurogene Inc. Breaks Ground in Rare Neurological Disorder Research with Expansion of NGN-401 Trial

Neurogene Inc., a leading clinical-stage company specializing in genetic medicines for rare neurological disorders, has recently announced its plans to expand its Phase 1/2 gene therapy clinical trial for NGN-401. This trial is particularly focused on female pediatric patients suffering from Rett syndrome, a debilitating genetic disorder that primarily affects the nervous system. In addition to expanding the trial, Neurogene Inc. also aims to improve the enrollment process to allow for faster participation and assessment.
Rett syndrome, although considered a rare condition, has a profound impact on the lives of patients and their families. It predominantly affects females and is caused by mutations in the MECP2 gene. Symptoms typically appear between six to eighteen months after birth and result in severe impairments in physical, cognitive, and social functioning. Children with Rett syndrome often lose purposeful hand skills, experience regression in language and motor abilities, exhibit repetitive hand movements, and develop respiratory irregularities. Currently, there is no cure for Rett syndrome, and treatment primarily focuses on managing symptoms and providing supportive care.

Eyenovia Inc

Eyenovia Inc Faces Challenges as Shares Plummet and Future Prospects Remain Uncertain



Eyenovia Inc, a major pharmaceutical preparations company, has witnessed a significant drop in its shares over the past month. This decline adds to the year-to-date poor performance. Additionally, the company is currently trading on the NASDAQ well below its 52-week average. These developments raise concerns about Eyenovia's future prospects and its ability to overcome these challenges. Furthermore, factors such as a co-promotion agreement and recent financial results also contribute to the uncertainty surrounding the company's future.
1. Co-Promotion Agreement with NovaBay Pharmaceuticals:
Eyenovia's strategic partnership with NovaBay Pharmaceuticals aims to expand market presence and provide a wider range of ophthalmic solutions. Under this agreement, NovaBay will market Eyenovia's Clobetasol propionate ophthalmic suspension, while Eyenovia will promote NovaBay's Avenova Antimicrobial Lid and Lash Solution. This collaboration intends to effectively target eye care professionals across the United States. However, the impact and success of this agreement remain to be seen.

Avenue Therapeutics Inc

Avenue Therapeutics Inc Sets New Standard for Seizure Treatment with BAER-101 Breakthrough

Avenue Therapeutics Inc, a prominent pharmaceutical company, has been making waves in the medical industry with its groundbreaking advancements in the treatment of various neurological disorders. Recently, the company presented its preclinical data on BAER-101 at the American Society for Experimental Neurotherapeutics Annual Meeting, showcasing its full suppression of seizure activity in absence epilepsy. This discovery has the potential to revolutionize anti-seizure drug development and significantly improve the lives of those affected by this condition.
Absence epilepsy is a neurological disorder characterized by intermittent episodes of unconsciousness and staring spells. It predominantly affects children and adolescents, often leading to academic and social challenges. The underlying cause of this condition involves abnormal electrical activity in the brain, resulting in seizures characterized by momentary lapses in consciousness. Prompt and effective treatment is crucial in preventing long-term complications and enhancing the quality of life for individuals with absence epilepsy.

Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.






 

Puretech Health Plc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com